The Singapore Economic Development Board (EDB), Singapore, says significant developments have taken place recently in R&D and manufacturing in the country. For example, Pfizer has expanded its nutrition manufacturing plant, making it among the largest worldwide. In addition, GlaxoSmithKline and EDB announced the first eight projects to be funded under the U.S. $24 million GSK-Singapore Partnership for Green & Sustainable Manufacturing. In R&D, Singapore-MIT Alliance for Research and Technology’s biotech spin-off — Visterra Singapore — raised U.S. $6 million in venture funding. Additionally, A*STAR research institutes announced their collaboration with Cytos Biotechnology and Life Technologies. Singapore also announced it is providing S$10 million funding for the Silver Community Test-Bed Program, which gives companies a mechanism to partner with the public sector in testing and developing healthcare innovations. Further, SingHealth officially launched its S$20 million Investigational Medicine Unit. Last, the National University of Singapore launched the NUS Initiative to Improve Health in Asia (NIHA), which comprises research, high-level policy forums, and leadership programs.